Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/CRSP
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Crispr Therapeutics AG (CRSP) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

CRISPR Therapeutics (CRSP) trades at $48.60, down 3.69% on the day, reflecting ongoing volatility. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal deep losses: gross margin -20.09%, net margin -56,853.4% in 2025. Recent Q1 2026 EPS missed expectations at -$1.28. However, analyst consensus remains bullish with a $74.50 price target, supported by Casgevy's FDA approval and pediatric expansion.
Outlook balances high growth potential in gene editing against significant financial risks. The company's robust cash position ($49.30M net inflow in 2025) and strong buy ratings (57.9% of analysts) suggest long-term opportunity, but persistent losses and competitive pressures require caution. Investors face upside from clinical successes versus downside from execution challenges and burn rate concerns.
Read full analysis

Key Stats

  • Market Cap
    $5.06B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $76.78
  • 52W Low
    $44.34
  • Typical Hold Time
    -
  • Enterprise Value
    $3.40B
  • Div Yield
    -
  • Trading Activity
    -
$48.82
52W Low: $44.34
30 Mar 2026
52W High: $76.78
08 Oct 2025

Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Most Recent News

Content is generated by Aura AI

Aduro and ECOCE complete Phase 1 of mapping flexible plastic waste in Mexico, starting HCT testing for circular recycling.

Aduro Clean Technologies and ECOCE have successfully completed Phase 1 of mapping flexible and multilayer plastic waste streams in Mexico, estimated at 1.5 million tons annually. The project now moves into testing these materials using Aduro's Hydroc...

Market News
1 hour ago
Na
Bullish
news icon
pluang ai news

Aduro and ECOCE advance to HCT testing for recycling Mexico's flexible plastic waste streams.

Aduro Clean Technologies and ECOCE have completed phase 1 of mapping flexible plastic waste streams in Mexico, estimated at 1.5 million tonnes annually. They are now moving selected post-consumer flexible packaging materials into Hydrochemolytic™ (HC...

Market News
1 hour ago
Na
Bullish
news icon
pluang ai news

FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patients

The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...

Market News
4 hours ago
Novartis
Bullish
news icon
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $5.06B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $76.78
  • 52W Low
    $44.34
  • Typical Hold Time
    -
  • Enterprise Value
    $3.40B
  • Div Yield
    -
  • Trading Activity
    -
$48.82
52W Low: $44.34
30 Mar 2026
52W High: $76.78
08 Oct 2025

Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!